More than 2 million men in the United States are prostate cancer survivors. Although prostate cancer is the second most common cancer among men, it can often be treated successfully. While some types of prostate cancer grow slowly and may need minimal or no treatment, other types are aggressive and can spread quickly. Screenings are crucial to detecting the disease while it’s still early.
Most prostate cancers are first found during a prostate-specific antigen (PSA) blood test or a digital rectal exam (DRE). Based on these results, your physician may schedule a biopsy to further examine your prostate. In a prostate biopsy, your prostate gland tissue is taken out with a biopsy needle. The tissue is checked to see if there are cancer or other abnormal cells in the prostate gland. Touro Infirmary is proud to introduce UroNav, a new cutting-edge option in prostate cancer detection.
What is UroNav?
The UroNav fusion biopsy system is a cutting-edge option for diagnosing prostate cancer for many patients with elevated and/or rising PSA levels. The UroNav combines pre-biopsy MR images with ultrasound technology to better detect suspicious lesions, delineation of the prostate and clear visualization of the biopsy needle.
- Robust, 3D gland segmentation modeling.
- Support for different biopsy approaches.
- Display of prior biopsy core locations and data from previous procedures.
- Elastic and rigid registration options, which allows the physician to select the registration technique best suited for the patient.
- Quick registration adjustments, which can be made in seconds without the need to restart the fusion procedure.
- Post-biopsy review provides multiple 2D and 3D views of the targets and biopsy core.
What are the benefits of UroNav?
- More accurate biopsies
- Improves accuracy
- Reduces discomfort
- Reduces the number of tissue samples taken
- Improves diagnosis
- Tumors are easily detected
Historically, urologists had a difficult time distinguishing between moderate and aggressive lesions in the prostate. UroNav is the next generation of prostate cancer detection because it accurately identifies and tests areas for more precise diagnosis.
Pints for Prostate
Dr. Richard Vanlangendonck, a board-certified urologist, fellowship-trained in minimally invasive urologic surgery, whose primary focus is on prostate and kidney cancers.